Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704881 | 0.98 | KMT2A (0.42) | KMT2AEPHX1HPGDLMNAL3MBTL1 | |
| SCHEMBL697496 | 0.93 | — | — | |
| SCHEMBL696966 | 0.88 | — | — | |
| SCHEMBL6321838 | 0.81 | EPHX1 (0.48) | KMT2AEPHX1HPGDLMNAL3MBTL1 | |
| SCHEMBL28191092 | 0.80 | EPHX1 (0.44) | KMT2AEPHX1HPGDLMNAL3MBTL1 | |
| SCHEMBL2078945 | 0.79 | KMT2A (0.47) | KMT2AEPHX1HPGDLMNAL3MBTL1 | |
| SCHEMBL2907815 | 0.78 | HPGD (0.48) | KMT2AHPGDLMNAALDH1A1 | |
| SCHEMBL314403 | 0.78 | L3MBTL1 (0.43) | KMT2AEPHX1HPGDLMNAL3MBTL1 | |
| SCHEMBL4189908 | 0.78 | KMT2A (0.45) | KMT2AEPHX1HPGDLMNAL3MBTL1 | |
| SCHEMBL10643879 | 0.78 | KMT2A (0.45) | KMT2AEPHX1HPGDLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212325-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Kukje Pharm. Ind. Co., Ltd. (KR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009066917-A2 | 2-ARYLMETHYLAZETIDINE-CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVE OR ITS SALT, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-05-28 | — | — | WO | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| EP-0295100-B1 | Methoxymethyl compounds | ERBA CARLO SPA (IT) | 1994-09-14 | — | — | EP | claimed |
| US-4952577-A | ANTIBIOTICS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1990-08-28 | — | — | US | claimed |
| EP-0295100-A1 | Methoxymethyl compounds | FARMITALIA CARLO ERBA S.r.l. (IT) | 1988-12-14 | — | — | EP | claimed |
| EP-3891134-A1 | PRODRUGS OF 4-((1R,3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND 4-((1/R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1-YL)-2,2-DIMETHY-1-(METHYL-D3)PIPERAZINE | H. Lundbeck A/S (DK) | 2021-10-13 | — | — | EP | disclosed |
| CN-113056457-A | 4- ((1R,3S) -6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl) -1,2, 2-trimethylpiperazine and 4- ((1R,3S) -6-chloro-3- (phenyl-d)5) -2, 3-dihydro-1H-inden-1-yl) -2, 2-dimethyl-1- (methyl-d3) Prodrugs of piperazine | H.隆德贝克有限公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2020114853-A1 | PRODRUGS OF 4-((1R,3S)-6-CHLORO-3-PHENYL-2,3-DIHYDRO-1H-INDEN-1-YL)-1,2,2-TRIMETHYLPIPERAZINE AND 4-((1/R,3S)-6-CHLORO-3-(PHENYL-D5)-2,3-DIHYDRO-1H-INDEN-1-YL)-2,2-DIMETHY-1-(METHYL-D3)PIPERAZINE | H. LUNDBECK A/S (DK) | 2020-06-11 | — | — | WO | disclosed |
| US-8778298-B2 | Isotope labeled 2-arylpropionic acid compounds and process for production of same, and molecular probe for positron emission tomography and method for imaging of cyclooxygenase and the like using same | RIKEN (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2463263-B1 | ISOTOPE LABELED 2-ARYLPROPIONIC ACID COMPOUNDS AND PROCESS FOR PRODUCTION OF SAME, AND MOLECULAR PROBE FOR POSITRON EMISSION TOMOGRAPHY AND METHOD FOR IMAGING OF CYCLOOXYGENASE AND THE LIKE USING SAME | RIKEN (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| US-8344002-B2 | Compound having β-secretase inhibitory activity | KISO YOSHIAKI (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| US-4847286-A | ANTIALLERGENS | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-07-11 | — | — | US | disclosed |
| EP-0293771-A2 | Cephalosporin compound and pharmaceutical composition thereof | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1988-12-07 | — | — | EP | disclosed |
| EP-0108942-B1 | CEPHALOSPORIN DERIVATIVES, METHODS OF PRODUCTION THEREOF AND PROPHYLACTIC AND THERAPEUTIC AGENTS FOR BACTERIAL INFECTION | KYOTO PHARMA IND (JP) | 1988-03-02 | — | — | EP | disclosed |
| US-4605651-A | BACTERICIDES | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0108942-A2 | Cephalosporin derivatives, methods of production thereof and prophylactic and therapeutic agents for bacterial infection | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | KMT2A 3544/4885EPHX1 490/4885HPGD 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.